Johnson & Johnson (NYSE: JNJ) reported strong financial results for the second quarter of 2025, exceeding analyst forecasts and increasing its full-year guidance. Strong results in its Innovative Medicine and MedTech businesses propelled the healthcare behemoth’s sales to $23.7 billion, a notable 5.8% gain. With adjusted EPS of $2.77, the company’s reported profits per share (EPS) increased by an astounding 18.7% to $2.29.
The company’s main section, Innovative Medicine, reported a 4.9% increase in sales, at $15.2 billion. The great performance of important medications, including the cancer therapies DARZALEX, CARVYKTI, ERLEADA, and RYBREVANT/LAZCLUZE, was the main driver of this growth. These products are still becoming more and more popular and gaining market share, which greatly boosts the segment’s earnings.
Read More: Johnson & Johnson Discontinued VENTURA Drug Development Program
Buoyed by the strong first-half performance, Johnson & Johnson has raised its full-year 2025 forecast. The company now expects reported sales growth of 5.4% at the midpoint, an increase of $2 billion from its previous guidance. The full-year EPS guidance has also been revised upwards by $0.25 to $10.85, with the adjusted operational EPS now projected to be $10.68 at the midpoint. This optimistic outlook reflects the company’s confidence in its product portfolio and its ability to execute its strategic initiatives.
Read More: Johnson & Johnson Launches MENTOR™ MemoryGel™ Breast Implants for Reconstruction Patients
In addition to its strong financial performance, Johnson & Johnson highlighted significant progress in its product pipeline. The company recently received approval for IMAAVY for the treatment of generalized myasthenia gravis, a chronic autoimmune, neuromuscular disease. Furthermore, the first cases with the OTTAVA™ Robotic Surgical System have been successfully completed, marking a key milestone in the development of this next-generation robotic-assisted surgery platform.
Last Modified:
